دورية أكاديمية
أعرض في EDS

Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.

التفاصيل البيبلوغرافية
العنوان: Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.
المؤلفون: Hamacher R; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; rainer.hamacher@uk-essen.de.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Pabst KM; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany., Cheung PF; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany., Heilig CE; Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany.; German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany., Hüllein J; Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany., Liffers ST; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany., Borchert S; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany., Costa PF; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany., Schaarschmidt BM; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, Germany., Kessler L; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany., Miera MA; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany., Droste M; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany., Akbulut M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany., Falkenhorst J; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Zarrad F; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany., Kostbade K; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Mavroeidi IA; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Glimm H; Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.; German Cancer Research Center, Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Consortium, Dresden, Germany; and., Umutlu L; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, Germany., Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Hübschmann D; German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.; Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany., Bauer S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany., Fröhling S; Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany.; German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany., Herrmann K; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany., Siveke JT; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany., Schildhaus HU; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany., Fendler WP; German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Feb 01; Vol. 65 (2), pp. 252-257. Date of Electronic Publication: 2024 Feb 01.
نوع المنشور: Observational Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Reston, VA : Society of Nuclear Medicine
Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc.
مواضيع طبية MeSH: Solitary Fibrous Tumors* , Quinolines* , Membrane Proteins* , Endopeptidases*, Humans ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Positron-Emission Tomography ; RNA, Messenger ; Positron Emission Tomography Computed Tomography
مستخلص: Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its potential use as a radiotheranostic target. Methods: We analyzed FAPα messenger RNA and protein expression in biopsy samples from SFT patients using immunohistochemistry and multiplexed immunofluorescence. Tracer uptake and detection efficacy were assessed in patients undergoing clinical 68 Ga-FAPα inhibitor (FAPI)-46 PET, 18 F-FDG PET, and contrast-enhanced CT. 90 Y-FAPI-46 radioligand therapy was offered to eligible patients with progressive SFT. Results: Among 813 patients and 126 tumor entities analyzed from the prospective observational MASTER program of the German Cancer Consortium, SFT ( n = 34) had the highest median FAPα messenger RNA expression. Protein expression was confirmed in tumor biopsies from 29 of 38 SFT patients (76%) in an independent cohort. Most cases showed intermediate to high FAPα expression by immunohistochemistry (24/38 samples, 63%), which was located primarily on the tumor cell surface. Nineteen patients who underwent 68 Ga-FAPI-46 PET imaging demonstrated significantly increased tumor uptake, with an SUV max of 13.2 (interquartile range [IQR], 10.2), and an improved mean detection efficacy of 94.5% (SEM, 4.2%), as compared with 18 F-FDG PET (SUV max , 3.2 [IQR, 3.1]; detection efficacy, 77.3% [SEM, 5.5%]). Eleven patients received a total of 34 cycles (median, 3 cycles [IQR, 2 cycles]) of 90 Y-FAPI-46 radioligand therapy, which resulted in disease control in 9 patients (82%). Median progression-free survival was 227 d (IQR, 220 d). Conclusion: FAPα is highly expressed by SFT and may serve as a target for imaging and therapy. Further studies are warranted to define the role of FAPα-directed theranostics in the care of SFT patients.
(© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
فهرسة مساهمة: Keywords: FAPI; SFT; radioligand; sarcoma; theranostic
المشرفين على المادة: EC 3.4.21.- (fibroblast activation protein alpha)
0Z5B2CJX4D (Fluorodeoxyglucose F18)
0 (Gallium Radioisotopes)
0 (RNA, Messenger)
0 (Quinolines)
0 (Membrane Proteins)
EC 3.4.- (Endopeptidases)
تواريخ الأحداث: Date Created: 20240104 Date Completed: 20240205 Latest Revision: 20240205
رمز التحديث: 20240205
DOI: 10.2967/jnumed.123.266411
PMID: 38176718
قاعدة البيانات: MEDLINE
الوصف
تدمد:1535-5667
DOI:10.2967/jnumed.123.266411